{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:35:31Z","timestamp":1698971731977},"reference-count":90,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,6,3]]},"DOI":"10.1080\/13543784.2021.1916466","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T07:19:20Z","timestamp":1619421560000},"page":"611-620","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients"],"prefix":"10.1080","volume":"30","author":[{"given":"Julie M.","family":"Asare","sequence":"first","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara A.","family":"Rabik","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-265884"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26909"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.251"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"issue":"21","key":"cit0006","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood.V116.21.2124.2124","volume":"116","author":"Watt TC","year":"2010","journal-title":"Blood"},{"issue":"1","key":"cit0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-017-0552-6","volume":"11","author":"Marin-Acevedo JA","year":"2018","journal-title":"J Hematol Oncol"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000401"},{"issue":"1","key":"cit0009","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"Wu J","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"2","key":"cit0010","first-page":"LBA","volume":"134","author":"Brown PA","year":"2019","journal-title":"Blood"},{"key":"cit0011","unstructured":"FDA. Summary of basis of approval \u2013 blincyto\u00ae, Amgen, Inc. 2018. (FDA) FaDA, editor. 2018."},{"key":"cit0012","unstructured":"Children\u2019s oncology group study AALL1331, risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL), ClinicalTrials.gov identifier NCT02101853. Version Date: 2\/6\/2019. 2019."},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005590"},{"key":"cit0014","unstructured":"Children\u2019s oncology group study AALL1821, A phase 2 study of blinatumomab (NSC #765986) in combination with nivolumab (NSC #748726), a checkpoint inhibitor of PD-1, in B-ALL patients aged 1\u201330 years with first relapse. Version Date: 9\/19\/2019. 2020."},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"issue":"1","key":"cit0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-017-0074-5","volume":"6","author":"N\u00e4gele V","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"issue":"8","key":"cit0023","doi-asserted-by":"crossref","first-page":"e27765","DOI":"10.1002\/pbc.27765","volume":"66","author":"Jones L","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128977"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25454"},{"issue":"5","key":"cit0026","doi-asserted-by":"crossref","first-page":"e28112","DOI":"10.1002\/pbc.28112","volume":"67","author":"Shah NN","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-794214"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0548-z"},{"key":"cit0030","unstructured":"A study to evaluate the efficacy and safety of daratumumab in pediatric and young adult participants greater than or equal to (\u2265)1 and less than or equal to (\u2264) 30 years of age with relapsed\/refractory precursor B-cell or T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03384654"},{"key":"cit0031","unstructured":"Hogan LE ALL breakout: new agents and relapse trials, children\u2019s oncology group fall meeting, 2020."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"cit0033","unstructured":"Corporation NP. Kymriah (tisagenlecleucel) [package insert]: u.S. food and drug administration website; 2017. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel"},{"key":"cit0034","unstructured":"Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD positive patients. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03876769"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279"},{"issue":"1","key":"cit0036","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood.V130.Suppl_1.810.810","volume":"130","author":"Qin H","year":"2017","journal-title":"Blood"},{"issue":"1","key":"cit0037","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","volume":"132","author":"Gardner RA","year":"2018","journal-title":"Blood"},{"key":"cit0038","unstructured":"A feasibility and safety study of dual specificity CD19 and CD22 CAR-T cell immunotherapy for CD19+CD22+ leukemia. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03330691"},{"key":"cit0039","unstructured":"Modified immune cells (CD19-CD22 CAR T cells) in treating patients with recurrent or refractory CD19 positive, CD22 positive leukemia or lymphoma. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04029038"},{"key":"cit0040","unstructured":"CD19\/CD22 chimeric antigen receptor (CAR) T cells in children and young adults with recurrent or refractory CD19\/CD22-expressing B cell malignancies. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03448393"},{"key":"cit0041","unstructured":"Phase I CD19\/CD22 chimeric antigen receptor T cells in peds recurrent\/refractory B cell malignancies. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03241940"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003293"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101097"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009928"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761320"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012823"},{"key":"cit0047","unstructured":"Autologous T-cells expressing a second generation CAR for treatment of T-cell malignancies expressing CD5 antigen. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03081910"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527"},{"key":"cit0049","unstructured":"Cell therapy for high risk T-cell malignancies using CD7-specific CAR expressed on autologous T cells. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03690011"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-019-00108-x"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0236"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738070"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707414"},{"issue":"1","key":"cit0056","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2019-126977","volume":"134","author":"Lacayo NJ","year":"2019","journal-title":"Blood"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.608"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0353"},{"key":"cit0059","unstructured":"A study of the safety and pharmacokinetics of venetoclax in pediatric and young adult patients with relapsed or refractory malignancies 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03236857?id=NCT03876769+OR+NCT03236857&draw=2&rank=2&load=cart"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0121"},{"key":"cit0061","unstructured":"Venetoclax combined with vyxeos (CPX-351) for participants with relapsed or refractory acute leukemia. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03826992"},{"issue":"31","key":"cit0062","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","volume":"28","author":"Arico M","year":"2010","journal-title":"J Clin Oncol"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.30"},{"issue":"21","key":"cit0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.V120.21.137.137","volume":"120","author":"Slayton WB","year":"2012","journal-title":"Blood"},{"issue":"15","key":"cit0066","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1200\/jco.2015.33.15_suppl.10006","volume":"33","author":"Slayton WB","year":"2015","journal-title":"J Clin Oncol"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70377-7"},{"key":"cit0068","unstructured":"Imatinib mesylate and combination chemotherapy in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03007147"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.116954"},{"issue":"7","key":"cit0070","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","volume":"109","author":"Carpenter PA","year":"2007","journal-title":"Blood"},{"issue":"5","key":"cit0071","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-5-29","volume":"8","author":"Chen H","year":"2012","journal-title":"J Hematol Oncol"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422691"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245944"},{"issue":"11","key":"cit0076","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","volume":"118","author":"Zhang J","year":"2011","journal-title":"Blood"},{"issue":"1","key":"cit0077","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1615\/CritRevOncog.v16.i1-2.30","volume":"16","author":"Tasian SK","year":"2011","journal-title":"Crit Rev Oncog"},{"issue":"6","key":"cit0078","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1084\/jem.201105802011512c","volume":"208","author":"Shochat C","year":"2011","journal-title":"J Exp Med"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415448"},{"key":"cit0080","unstructured":"A phase 2 study of ruxolitinib with chemotherapy in children with acute lymphoblastic leukemia. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02723994"},{"key":"cit0081","unstructured":"Ruxolitinib phosphate or dasatinib with chemotherapy in treating patients with relapsed or refractory Philadelphia chromosome-like acute lymphoblastic leukemia. Available From: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02420717"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90034-X"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.46.120604.141300"},{"issue":"11","key":"cit0084","first-page":"2615","volume":"59","author":"Adams J","year":"1999","journal-title":"Cancer Res"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.252462599"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2173"},{"issue":"2","key":"cit0088","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15919","volume":"186","author":"Horton TM","year":"2019","journal-title":"Br J Haematol"},{"key":"cit0089","unstructured":"Combination chemotherapy with or without bortezomib in treating younger patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02112916"},{"issue":"6","key":"cit0090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/pbc.25937","volume":"63","author":"Shah NN","year":"2016","journal-title":"Pediatr Blood Cancer"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1916466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T18:49:30Z","timestamp":1698950970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1916466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":90,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,3]]}},"alternative-id":["10.1080\/13543784.2021.1916466"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1916466","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}